Monsoon Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Global retina expert joins to support sozinibercept development and launch preparationMELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani i

MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive

MELBOURNE, Australia, Dec. 19, 2023 -- Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced...

First patient dosed in Australia where 3 clinical trial sites have been activated.The trial will enrol advanced colorectal cancer patients whose cancer...

Opthea to Present at the FLORetina 2023 Congress Melbourne, Australia; 30 November 2023 - Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies...